trending Market Intelligence /marketintelligence/en/news-insights/trending/5Jw8z0kWcOTk3nXzUdyyBA2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

TG Therapeutics phase 3 trial for leukemia treatment meets primary endpoint

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Blog

Corporate Credit Risk Trends in Developing Markets: A Probability of Default Perspective


TG Therapeutics phase 3 trial for leukemia treatment meets primary endpoint

TG Therapeutics Inc. said its phase 3 study of TG-1101, or ublituximab, in combination with ibrutinib, in patients with previously treated high risk chronic lymphocytic leukemia, met its primary endpoint.

Treatment with ublituximab plus ibrutinib reached a 78% overall response rate with a 7% complete response rate, compared to 45% overall response rate with 0% complete response rate for ibrutinib alone.

Additionally, 19% minimal residual disease, or MRD, negativity was observed in the experimental arm, compared to 2% MRD negativity for ibrutinib alone.

Ublituximab is a novel, glycoengineered monoclonal antibody that targets certain white blood cells.